{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Elurbide J"],"funding":["Bundesministerium für Bildung und Forschung","Erasmus Program","Fundación M Torres","Departamento de Educación, Gobierno de Navarra","ERA-NET TRANSCAN-3","Fundación Mario Losantos","European Cooperation in Science and Technology","European Commission","Universidad Complutense de Madrid","&apos;la Caixa&apos; Foundation","Ministerio de Ciencia, Innovación y Universidades MCINN","Ministerio de Sanidad, Política Social e Igualdad","Deutsche Forschungsgemeinschaft","Instituto de Salud Carlos III","Ministerio de Ciencia e Innovación","Juan Serra Foundation","Fundación Científica Asociación Española Contra el Cáncer","Max Planck Gesellschafts","Fundación Eugenio Rodriguez Pascual"],"pagination":["116-127"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12056590"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["74(1)"],"pubmed_abstract":["<h4>Background</h4>Cholangiocarcinoma (CCA) is a very difficult-to-treat cancer. Chemotherapies are little effective and response to immune checkpoint inhibitors is limited. Therefore, new therapeutic strategies need to be identified.<h4>Objective</h4>We characterised the enzyme protein arginine-methyltransferase 5 (PRMT5) as a novel therapeutic target in CCA.<h4>Design</h4>We evaluated the expression of PRMT5, its functional partner MEP50 and methylthioadenosine phosphorylase (MTAP)-an enzyme that modulates the sensitivity of PRMT5 to pharmacological inhibitors-in human CCA tissues. PRMT5-targeting drugs, currently tested in clinical trials for other malignancies, were assessed in human CCA cell lines and organoids, as well as in two immunocompetent CCA mouse models. Transcriptomic, prote"],"journal":["Gut"],"pubmed_title":["Identification of PRMT5 as a therapeutic target in cholangiocarcinoma."],"pmcid":["PMC12056590"],"funding_grant_id":["PID2020-117116RB-I00 CEX2021-001136-S","AC23_1/00008","Funding for M.A.A, M.G.F-B, C.B","COST Action Precision-BTC-Network CA22125","Sara Borrell Contract CD22/00109","HORIZON-HLTH-2022-STAYHLTH-02 No 101095679","Ramón y Cajal Program contract RYC2018-024475-1","2022","Funding for M.A.A, M. G. F.B, C.B","PID2022-136616OB-I00/AEI/10.13039/501100011033","Fellowship to LC","2021-1-IT02-KA131-HED-000008150 Placedoc fellowshi","LiSYM-KREBS, DEEP-HCC","Fellowship to B.C-U","Predoctoral fellowship PREP2022-000609","Caixa Impulse Innovation 2023 (CI23-20155)","LABAE20011GARC","S2022/BMD-7409","TRNSC235657AVIL","TRANSCAN2022-784-024","Post-doctoral contract POSTD18014AREC","TR285/10-2","PID2020-117941RB-I00/AEI/10.13039/501100011033"],"pubmed_authors":["Trautwein C","Huch M","Aldrighetti L","Latasa MU","Krawczyk M","Valbuena E","Wu H","Sangro B","Urman JM","Martinez-Chantar ML","Lopez-Pascual A","Cubero FJ","Elurbide J","Berasain C","Schneider KM","Mariani S","Castello-Uribe B","Azkargorta M","Arechederra M","Martinez-Perez LA","Adan-Villaescusa E","Amat I","G Fernandez-Barrena M","Casadei Gardini A","Marin JJG","Colyn L","Uriarte I","Arnes-Benito R","Avila MA","Ratti F","Elortza F"],"additional_accession":[]},"is_claimable":false,"name":"Identification of PRMT5 as a therapeutic target in cholangiocarcinoma.","description":"<h4>Background</h4>Cholangiocarcinoma (CCA) is a very difficult-to-treat cancer. Chemotherapies are little effective and response to immune checkpoint inhibitors is limited. Therefore, new therapeutic strategies need to be identified.<h4>Objective</h4>We characterised the enzyme protein arginine-methyltransferase 5 (PRMT5) as a novel therapeutic target in CCA.<h4>Design</h4>We evaluated the expression of PRMT5, its functional partner MEP50 and methylthioadenosine phosphorylase (MTAP)-an enzyme that modulates the sensitivity of PRMT5 to pharmacological inhibitors-in human CCA tissues. PRMT5-targeting drugs, currently tested in clinical trials for other malignancies, were assessed in human CCA cell lines and organoids, as well as in two immunocompetent CCA mouse models. Transcriptomic, prote","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2026-07-15T11:11:44.106Z","creation":"2026-07-05T03:08:20.325Z"},"accession":"S-EPMC12056590","cross_references":{"pubmed":["39266051"],"doi":["10.1136/gutjnl-2024-332998"]}}